more lipid drugs get indications based on HARD clinical outcomes

You'll start to see more lipid drugs get indications based on HARD clinical outcomes...such as reducing MI or stroke risk.

Drugs are often approved just due to their ability to improve SURROGATE endpoints...lipids, blood pressure, glucose, etc.

For example, the omega-3 fatty acid, Vascepa (icosapent ethyl) is currently approved JUST to lower triglycerides ≥ 500 mg/dL...NOT to lower the risk of CV events or pancreatitis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote